Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT

Enke Baldini1, Yannick Arlot-Bonnemains2, Salvatore Sorrenti3, Caterina Mian4, Maria R Pelizzo4, Enrico De Antoni3, Silvio Palermo3, Stefania Morrone1, Susi Barollo5, Angela Nesca1, Costanzo G Moretti6, Massimino D'Armiento1 and Salvatore Ulisse1*

Author Affiliations

1 Department of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy

2 CNRS-UMR 6061 "Génétique et Développement", IFR 140 G.F.A.S., Faculté de Médecine, Université Rennes 1, Rennes, France

3 Department of Surgical Sciences, "Sapienza" University of Rome, Rome, Italy

4 Department of Medical and Surgical Sciences, University of Padova, Padova, Italy

5 Veneto Institute of Oncology IOV - IRCCS, Padova, Italy

6 Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy

For all author emails, please log on.

BMC Cancer 2011, 11:411  doi:10.1186/1471-2407-11-411

Published: 26 September 2011

Abstract

Background

The Aurora kinase family members, Aurora-A, -B and -C, are involved in the regulation of mitosis, and alterations in their expression are associated with cell malignant transformation. To date no information on the expression of these proteins in medullary thyroid carcinoma (MTC) are available. We here investigated the expression of the Aurora kinases in human MTC tissues and their potential use as therapeutic targets.

Methods

The expression of the Aurora kinases in 26 MTC tissues at different TNM stages was analyzed at the mRNA level by quantitative RT-PCR. We then evaluated the effects of the Aurora kinase inhibitor MK-0457 on the MTC derived TT cell line proliferation, apoptosis, soft agar colony formation, cell cycle and ploidy.

Results

The results showed the absence of correlation between tumor tissue levels of any Aurora kinase and tumor stage indicating the lack of prognostic value for these proteins. Treatment with MK-0457 inhibited TT cell proliferation in a time- and dose-dependent manner with IC50 = 49.8 ± 6.6 nM, as well as Aurora kinases phosphorylation of substrates relevant to the mitotic progression. Time-lapse experiments demonstrated that MK-0457-treated cells entered mitosis but were unable to complete it. Cytofluorimetric analysis confirmed that MK-0457 induced accumulation of cells with ≥ 4N DNA content without inducing apoptosis. Finally, MK-0457 prevented the capability of the TT cells to form colonies in soft agar.

Conclusions

We demonstrate that Aurora kinases inhibition hampered growth and tumorigenicity of TT cells, suggesting its potential therapeutic value for MTC treatment.